Yiqing oral liquid in the treatment of novel coronavirus infection randomized controlled clinical studies

Huashan Hospital Affiliated to Fudan University0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•(1) The Ct value of both N gene and ORF gene in the nucleic acid detection of novel coronavirus infection is less than 30 (fluorescence quantitative PCR method, the limit value is 40);
•(2) Age 18-85 years old;
•(3) The clinical classification belongs to light, common and heavy;
•(4) More than 1 high-risk factor for progression to severe/critical illness;
•(5) Voluntarily sign a written informed consent.

•(1) Pregnant and lactating women;
•(2) Those with allergic constitution (referring to those allergic to the above drugs or foods or to the known ingredients of the drug in this trial);
•(3) mentally ill, or incapable of self-awareness;
•(4) Patients taking other antiviral drugs (including proprietary Chinese medicines);
•(5) Mechanical ventilation is being used or is expected to be urgently needed;
•(6) Patients with severe acute heart, brain, kidney, digestive tract and other diseases (such as acute heart failure, acute myocardial infarction, acute cerebrovascular disease, renal failure requiring dialysis treatment, acute gastrointestinal bleeding, etc.), ALT, AST more than 3 times the upper limit of normal;
•(7) Suspected or confirmed severe active bacterial, fungal, tuberculosis or other infections (except for COVID-19);
•(8) Those who have other circumstances that the investigator considers unsuitable to participate in clinical trials.

发起方

Huashan Hospital Affiliated to Fudan University